Belzutifan is a inhibitor that goes after HIF-2, a protein that usually shows up more in RCC with VHL syndrome. The drug is made to cut down on the signals that tumors use to respond to low oxygen levels. It comes as 40 mg pills with a coating.
You’re supposed to take 120 mg of it, just once every day. You’ll find this drug in bottles with 90 tablets in each. Belzutifan does its job by keeping HIF-2 under control.
This helps cells act normally in low-oxygen situations, stopping the growth of new blood vessels and cell growth. It’s often used for treating kidney cancer that doesn’t get better with other treatments or when you don’t have many options left.
